0714/25SCR019-18/R10RGB
Media Highlights
From the 2025 ASCO® Annual Meeting
1
Media Outlet Article / Coverage
Blood Cancers Today
Second-line ASC Monotherapy Safely Elicits High Molecular Response
Rates in Non-T315l-Mutant CML-CP
The Healthbook Company Ltd.
Healthbook CHICAGO 2025 Newsroom
Oncology Learning Network
Asciminib Demonstrates High Molecular Responses Among Patients With
CML-CP
Targeted Oncology
ASC2ESCALATE Clinical Trial in CML: Asciminib Dose Escalation Strategy
Targeted Oncology
Interim Analysis Highlights Asciminib's Efficacy and Safety in Second-
Line CML
VuMedi
ASCO® 2025 Insights: Efficacy & Safety of Asciminib in Patients With CP-
CML After 1 TKI - Interim Analysis of the Ph2 ASC2ESCALATE Trial
David Andorsky, MD
SCRI at Rocky Mountain Cancer Centers I The US Oncology Network
Media Outlet Article / Coverage
Cancer Network
Spotlighting Key Upcoming Presentations Across Oncology at ASCO
2025
Benjamin Garmezy, MD
SCRI
Media Outlet Article / Coverage
ASCO Daily News
Podcast: ASCO25 Preview: Key Research Accelerating Cancer Care
ASCO Daily News
ASCO25 First Look: Dr. Erika Hamilton on VERITAC-2
ASCO Daily News
VERITAC-2: Vepdegestrant Delivers Significantly Longer PFS Than
Fulvestrant in ESR1-Mutated, ER-Positive/HER2-Negative Advanced
Breast Cancer
ASCO Daily News
Podcast: Day 2: Top Takeaways From ASCO25
ASCO Daily News
Podcast: ASCO25 Recap: CHALLENGE, DESTINY-Breast09, and
More
Erika Hamilton, MD
SCRI
Continued ➔
